热门资讯> 正文
Travere Therapeutics将就肾脏疾病治疗提交SNDA
2025-02-11 20:51
- Sonida Senior Living, Inc. Common Stock(SNDA) 0
- TRAVERE THERAPEUTICS(TVTX) 0
- DUET Acquisition Corp Ordinary Shares - Class A(DUET) 0
- Travere Therapeutics (NASDAQ:TVTX) completed its Type C meeting with the U.S. Food and Drug Administration and plans to submit a supplemental New Drug Application seeking traditional approval of FILSPARI for focal segmental glomerulosclerosis, a rare kidney disorder.
- The sNDA will be based on existing data from the Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI and is expected to be submitted around the end of the first quarter of 2025.
- Source: Press Release
More on Travere Therapeutics
- Travere Therapeutics: Cautiously Bullish Based On Improving Revenue
- Vertex leads J.P. Morgan's top biotech picks list for 2025
- Seeking Alpha’s Quant Rating on Travere Therapeutics
- Historical earnings data for Travere Therapeutics
- Financial information for Travere Therapeutics
推荐文章
一周财经日历丨降息信号将定？下周全球央行年会成关键；小米、泡泡玛特、快手领衔港股财报潮
港股周报丨见证历史！南向资金单日疯狂买入港股359亿港元；腾讯绩后股价一度升破600港元
特朗普政府据悉考虑动用芯片法案资金来入股英特尔
美股机会日报丨“恐怖数据”符合预期，交易员下调美联储降息预期；巴菲特Q2新建仓股飙升，联合健康盘前涨超10%
银诺医药-B上市首日暴涨285%，一手赚超1万港元
投资大佬Tepper减持阿里巴巴、京东等 买入股价暴跌的联合健康
伯克希尔减持苹果股份 增持联合健康集团
8月15日外盘头条：特朗普政府洽购英特尔股份 贝森特否认推动降息 苹果重新设计Apple Watch血氧功能
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
